Penn and CHOP researchers want to develop urea cycle disorder treatments using CRISPR gene-editing therapy. Get unlimited access to Inquirer.com and The Inquirer App, plus 5 articles each month to ...
The FDA’s Marty Makary and Vinay Prasad have laid out a path for CRISPR treatments on demand. An expert weighs in on what it ...
Ecuadorian scientists have, for the first time, edited the gene of a fungus that destroys banana plantations. Using an ...
Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as the company investigates and works with regulators on its CRISPR-based ...
Detailed price information for Caribou Biosciences Inc (CRBU-Q) from The Globe and Mail including charting and trades.
Detailed price information for Caribou Biosciences Inc (CRBU-Q) from The Globe and Mail including charting and trades.
Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...
Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...
This manuscript reports on the application of ribosome profiling (EZRA-seq and eRF1-seq) combined with massively parallel reporter assays to identify and characterize a GA-rich element associated with ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies ...
The clinical hold follows Intellia's disclosure that it paused dosing in two Phase III trials after a patient experienced a serious adverse event.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback